Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biomx Ltd (NY: PHGE ) 0.2238 -0.0042 (-1.84%) Official Closing Price Updated: 8:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biomx Ltd < Previous 1 2 3 4 5 Next > This Healthcare Stock is Down By More Than 50%: Here's 25 Stocks Moving Premarket July 13, 2022 Gainers Via Benzinga The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate July 06, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange July 06, 2022 From BiomX Inc. Via Business Wire Why BiomX Shares Are Trading Higher Today? June 28, 2022 Via Benzinga BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed May 24, 2022 Via Benzinga Earnings Scheduled For May 11, 2022 May 11, 2022 Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter. Via Benzinga Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session June 28, 2022 Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 28, 2022 Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning! Via InvestorPlace Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers June 28, 2022 From BiomX Inc. Via Business Wire BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis June 27, 2022 From BiomX Inc. Via Business Wire Stocks That Hit 52-Week Lows On Friday June 03, 2022 During Friday's trading, 69 companies set new 52-week lows. Via Benzinga The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures May 24, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga BiomX Announces Corporate Restructuring May 24, 2022 From BiomX Inc. Via Business Wire BiomX Announces Publication in the Journal, Bioinformatics May 20, 2022 From BiomX Inc. Via Business Wire BiomX Reports First Quarter 2022 Financial Results and Provides Business Update May 11, 2022 From BiomX Inc. Via Business Wire BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients May 06, 2022 From BiomX Inc. Via Business Wire BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022 May 05, 2022 From BiomX Inc. Via Business Wire 103 Biggest Movers From Yesterday May 11, 2022 Gainers Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday April 06, 2022 Good morning! Another day of trading lies ahead and we're starting it off with the biggest pre-market stock movers for Wednesday! Via InvestorPlace Earnings Scheduled For March 30, 2022 March 30, 2022 Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021. Via Benzinga BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update March 30, 2022 From BiomX Inc. Via Business Wire The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More March 27, 2022 Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. Via Benzinga BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022 March 23, 2022 From BiomX Inc. Via Business Wire BiomX Presenting at Three Upcoming Investor Conferences February 24, 2022 From BiomX Inc. Via Business Wire BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation January 04, 2022 From BiomX Inc. Via Business Wire Earnings Scheduled For November 15, 2021 November 15, 2021 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to... Via Benzinga 52 Biggest Movers From Yesterday October 20, 2021 Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares climbed 42.6% to close at $9.51 on Tuesday. Xiaobai Maimai said Xiaobao An resigned as CEO. Kaival Brands Innovations Group... Via Benzinga BiomX's Acne Vulgaris Treatment Fails To Top Vehicle Treatment Cohort October 18, 2021 BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects. A statistically significant... Via Benzinga The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal October 13, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... Via Benzinga Exposures Product Safety BiomX Enters Agreement Granting Maruho Co. A right Of First Offer To License BiomX's Atopic Dermatitis Product Candidate BX005; Maruho Will Also Enter Binding Agreement For $3M Equity Investment In BiomX October 13, 2021 BiomX Inc. (NYSE: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.